Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR[R43/R44])

The summary for the Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR[R43/R44]) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR[R43/R44]): Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to continue and expand non-clinical and pre-clinical efforts for product development of radiological/nuclear medical countermeasures effective for 1) the mitigation or treatment of acute radiation syndromes and long-term or delayed effects, 2) the treatment of internal radionuclide contamination with decorporation agents, and 3) the determination of individual radiation exposure levels with radiation biodosimetry products for potential use during a radiological emergency.Applications proposing candidate product(s) that mitigate and/or treat acute and long-term radiation injury due to lethal exposures or facilitate the elimination of internal radionuclide contamination; or that propose means of accurately estimating radiation dose received (biodosimetry) are solicited.Applications should support product development efforts leading to the submission of Investigational New Drug Applications (IND) or Investigational Device Exemptions (IDE) to the U.S. Food and Drug Administration (FDA) to facilitate eventual licensure and potential inclusion in the Strategic National Stockpile (SNS). Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I and Phase II applications.